OpenAlex
PricingAboutJobs
Log inGet started
Work

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

HTML

Year: 2019
Type: conference-abstract
Source: Cancer Research
DOI: 10.1158/1538-7445.sabcs18-gs1-04
Authors: LA Emens, S Loi, HS Rugo, A Schneeweiss, V Diéras, H Iwata, CH Barrios, M Nechaeva, L Molinero, A Nguyen Duc, R Funke, SY Chui, A Husain, EP Winer, S Adams, P Schmid
Institutions: Johns Hopkins University, Queen Mary University of London, University of California, San Francisco, Peter MacCallum Cancer Centre, University Hospital Heidelberg, NYU Langone Health, Centre Eugène Marquis, Dana-Farber Cancer Institute, Aichi Cancer Center Hospital
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, locally advanced breast cancer, PD-L1 expression, tumor-infiltrating immune cells, stromal tumor-infiltrating lymphocytes, immunological markers, predictive biomarkers, first-line therapy, progression-free survival, overall survival, BRCA1/2 mutation status, HER2
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2944446380
Cites:
Cited by: 91
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security